What Is Claimed Is:

Claim 1. A B7-H3 binding molecule, wherein said molecule is an isolated antibody, an immunoreactive fragment thereof, or a diabody, which comprises a variable domain that specifically binds an extracellular domain of B7-H3, wherein said molecule:

(A) binds to 4Ig and 2Ig isoforms of B7-H3 that is endogenously expressed on the surface of a cancer cell;

(B) is internalized upon binding to B7-H3 expressed on the surface of a cancer cell; and

(C) comprises a variable domain that comprises or retains the binding specificity of:

(1) a light chain variable domain that comprises CDR_1 (SEQ ID NO: 21), CDR_2 (SEQ ID NO: 23) and CDR_3 (SEQ ID NO: 25), and a heavy chain variable domain that comprises CDR_1 (SEQ ID NO: 29), CDR_2 (SEQ ID NO: 31) and CDR_3 (SEQ ID NO: 33);

(2) a light chain variable domain that comprises CDR_1 (SEQ ID NO: 5), CDR_2 (SEQ ID NO: 7) and CDR_3 (SEQ ID NO: 9), and a heavy chain variable domain that comprises CDR_1 (SEQ ID NO: 13), CDR_2 (SEQ ID NO: 15) and CDR_3 (SEQ ID NO: 17); or

(3) a light chain variable domain that comprises CDR_1 (SEQ ID NO: 37), CDR_2 (SEQ ID NO: 39) and CDR_3 (SEQ ID NO: 41), and a heavy chain variable domain that comprises CDR_1 (SEQ ID NO: 45), CDR_2 (SEQ ID NO: 47) and CDR_3 (SEQ ID NO: 49).

Claim 2. The B7-H3 binding molecule of claim 1, which is a humanized monoclonal antibody.

Claim 3. The B7-H3 binding molecule of any of claims 1-2, wherein said molecule comprises a variant human IgG1 Fc region, wherein said variant human IgG1 Fc region comprises at least one amino acid modification relative to a wild-

type Fc region, said amino acid modification(s) comprising amino acid modification(s) that alters the affinity or avidity of said variant Fc region for binding to an FcγR such that said molecule exhibits enhanced effector function relative to said wild-type Fc region.

Claim 4. The B7-H3 binding molecule of claim 3, wherein said Fc region modification comprises:

(A) at least one substitution selected from the group consisting of:

(1) F243L;

(2) D270E;

(3) R292P;

(4) S298N;

(5) Y300L;

(6) V305I;

(7) A330V; and

(8) P396L;

(B) at least one substitution of two amino acid residues, said substitutions being selected from the group consisting of:

(1) F243L and P396L;

(2) F243L and R292P; and

(3) R292P and V305I;

(C) at least one substitution of three amino acid residues, said substitutions being selected from the group consisting of:

(1) F243L, R292P and Y300L;

(2) F243L, R292P and V305I;

(3) F243L, R292P and P396L; and

(4) R292P, V305I and P396L;

(D) at least one substitution of four amino acid residues, said substitutions being selected from the group consisting of:

(1) F243L, R292P, Y300L and P396L; and

(2) F243L, R292P, V305I and P396L;

or

(E) a substitution of at least the five amino acid residues: F243L, R292P, Y300L, V305I and P396L;

wherein said numbering is according to the Kabat numbering scheme.

Claim 5. The B7-H3 binding molecule of claim 3, wherein said Fc region modification comprises substitutions of:

(A) F243L, R292P, and Y300L;

(B) L235V, F243L, R292P, Y300L, and P396L; or

(C) F243L, R292P, Y300L, V305I, and P396L;

wherein said numbering is according to the Kabat numbering scheme.

Claim 6. The B7-H3 binding molecule of claim 5, wherein said molecule comprises:

(A) a light chain variable domain that comprises CDR_1 (SEQ ID NO: 5), CDR_2 (SEQ ID NO: 7) and CDR_3 (SEQ ID NO: 9) and a heavy chain variable domain that comprises CDR_1 (SEQ ID NO: 13), CDR_2 (SEQ ID NO: 15) and CDR_3 (SEQ ID NO: 17); and

(B) an Fc region modification that comprises the substitutions: L235V, F243L, R292P, Y300L, and P396L;

wherein said numbering is according to the Kabat numbering scheme.

Claim 7. The B7-H3 binding molecule of claim 6, wherein said molecule is a chimeric antibody.

Claim 8. The B7-H3 binding molecule of claim 6, wherein said molecule is a humanized antibody.

Claim 9. The B7-H3 binding molecule of claim 1, wherein said molecule comprises:

(A) a light chain variable domain having the amino acid sequence of SEQ ID NO: 89;

(B) a heavy chain variable domain having the amino acid sequence of SEQ ID NO: 99; and

(C) an Fc-region having the substitutions: L235V, F243L, R292P, Y300L, and P396L;

wherein said numbering is according to the Kabat numbering scheme.

Claim 10. A hybridoma that secretes the isolated antibody of claim 1.

Claim 11. An isolated nucleic acid molecule that encodes a polypeptide chain of the B7-H3 binding molecule of any of claims 1-9.

Claim 12. The B7-H3 binding molecule of claim 1, wherein said molecule is a diabody comprising:

(A) a polypeptide chain I that comprises an immunoglobulin VL epitope binding domain specific for binding B7-H3 and a VH epitope binding domain specific for binding a molecule other than B7-H3; and

(B) a polypeptide chain II that comprises an immunoglobulin VH epitope binding domain specific for binding B7-H3 and a VL epitope binding domain specific for binding said molecule other than B7-H3;

wherein said polypeptide chains I and II are associated together so as to form functional epitope binding domains capable of binding to B7-H3 and said molecule other than B7-H3.

Claim 13. The B7-H3 binding molecule of claim 12, wherein said molecule other than B7-H3 is a hapten.

Claim 14. The B7-H3 binding molecule of claim 13, wherein said hapten is fluorescein isothiocyanate.

Claim 15. The B7-H3 binding molecule of claim 12, wherein said molecule other than B7-H3 is a T-Cell Receptor or the NKG2D receptor.

Claim 16. The B7-H3 binding molecule of claim 12, wherein said molecule other than B7-H3 is a tumor-associated antigen.

Claim 17. The B7-H3 binding molecule of claim 16, wherein said tumor-associated antigen is selected from the group consisting of A33; ADAM-9; ALCAM; BAGE; beta-catenin; CA125; Carboxypeptidase M; CD103; CD19; CD20; CD22; CD23; CD25; CD27; CD28; CD36; CD40/CD154; CD45; CD46; CD5; CD56; CD79a/CD79b; CDK4; CEA; CTLA4; Cytokeratin 8; EGF-R; EphA2; ErbB1; ErbB3; ErbB4; GAGE-1; GAGE-2; GD2/GD3/GM2; gp100; HER-2/neu; human papillomavirus-E6; human papillomavirus-E7; Integrin Alpha-V-Beta-6; JAM-3; KID3; KID31; KSA (17-1A); LUCA-2; MAGE-1; MAGE-3; MART; MUC-1; MUM-1; N-acetylglucosaminyltransferase; Oncostatin M;

p15; PIPA; PSA; PSMA; ROR1; sTn; TNF-ß receptor; TNF-α receptor; TNF-γ receptor; Transferrin Receptor; and VEGF receptor.

Claim 18. A nucleic acid molecule that encodes a polypeptide chain of the B7-H3 binding molecule of any of claims 12-17.

Claim 19. A pharmaceutical composition comprising (i) a therapeutically effective amount of the B7-H3 binding molecule of any of claims 1-9 or 12-17 and (ii) a pharmaceutically acceptable carrier.

Claim 20. The pharmaceutical composition of claim 19, which further comprises one or more additional anti-cancer agents.

Claim 21. The pharmaceutical composition of claim 20, wherein said additional anti-cancer agent is a chemotherapeutic agent, a radiation therapeutic agent, a hormonal therapeutic agent, a toxin or an immunotherapeutic agent.

Claim 22. The pharmaceutical composition of claim 20, wherein said additional anti-cancer agent is a toxin selected from the group consisting of: a taxane, a maytansinoid, an auristatin, a calicheamicin, an anthracycline, a CC-1065 analog, docetaxel, a cathepsin, ricin, gelonin, Pseudomonas exotoxin, diphtheria toxin, RNase, and a toxic radioisotope.

Claim 23. The use of the B7-H3 binding molecule of any of claims 1-9 or 12-17 or of the pharmaceutical composition of any of claims 19-22 in the preparation of a medicament for the treatment of cancer in a patient.

Claim 24. The use of the B7-H3 binding molecule of claim 23, characterised in that said cancer is characterized by the presence of a cancer cell selected from the group consisting of a cell of an adrenal gland tumor, an AIDS-associated cancer, an alveolar soft part sarcoma, an astrocytic tumor, bladder cancer, bone cancer, a brain and spinal cord cancer, a metastatic brain tumor, a breast cancer, a carotid body tumors, a cervical cancer, a chondrosarcoma, a chordoma, a chromophobe renal cell carcinoma, a clear cell carcinoma, a colon cancer, a colorectal cancer, a cutaneous benign fibrous histiocytoma, a desmoplastic small round cell tumor, an ependymoma, a Ewing's tumor, an

extraskeletal myxoid chondrosarcoma, a fibrogenesis imperfecta ossium, a fibrous dysplasia of the bone, a gallbladder or bile duct cancer, gastric cancer, a gestational trophoblastic disease, a germ cell tumor, a head and neck cancer, hepatocellular carcinoma, an islet cell tumor, a Kaposi's Sarcoma, a kidney cancer, a leukemia, a lipoma/benign lipomatous tumor, a liposarcoma/malignant lipomatous tumor, a liver cancer, a lymphoma, a lung cancer, a medulloblastoma, a melanoma, a meningioma, a multiple endocrine neoplasia, a multiple myeloma, a myelodysplastic syndrome, a neuroblastoma, a neuroendocrine tumors, an ovarian cancer, a pancreatic cancer, a papillary thyroid carcinoma, a parathyroid tumor, a pediatric cancer, a peripheral nerve sheath tumor, a phaeochromocytoma, a pituitary tumor, a prostate cancer, a posterious uveal melanoma, a rare hematologic disorder, a renal metastatic cancer, a rhabdoid tumor, a rhabdomysarcoma, a sarcoma, a skin cancer, a soft-tissue sarcoma, a squamous cell cancer, a stomach cancer, a synovial sarcoma, a testicular cancer, a thymic carcinoma, a thymoma, a thyroid metastatic cancer, and a uterine cancer.

What Is Claimed Is:

Claim 1. An isolated antibody or an immunoreactive fragment thereof, wherein said isolated antibody or said fragment comprises a variable domain that specifically binds an extracellular domain of B7-H3, wherein said antibody competes for binding to said B7-H3 with any of antibodies: BRCA69D, BRCA84D, or PRCA157.

Claim 2. The isolated antibody or immunoreactive fragment thereof of claim 1, wherein said antibody or said fragment comprises a variable domain that comprises:

(A) CDR_1 (**SEQ ID NO: 21**), CDR_2 (**SEQ ID NO: 23**) and CDR_3 (**SEQ ID NO: 25**) of the light chain of BRCA69D and CDR_1 (**SEQ ID NO: 29**), CDR_2 (**SEQ ID NO: 31**) and CDR_3 (**SEQ ID NO: 33**) of the heavy chain of BRCA69D;

(B) CDR_1 (**SEQ ID NO: 5**), CDR_2 (**SEQ ID NO: 7**) and CDR_3 (**SEQ ID NO: 9**) of the light chain of BRCA84D and CDR_1 (**SEQ ID NO: 13**), CDR_2 (**SEQ ID NO: 15**) and CDR_3 (**SEQ ID NO: 17**) of the heavy chain of BRCA84D; or

(C) CDR_1 (**SEQ ID NO: 37**), CDR_2 (**SEQ ID NO: 39**) and CDR_3 (**SEQ ID NO: 41**) of the light chain of PRCA157 and CDR_1 (**SEQ ID NO: 45**), CDR_2 (**SEQ ID NO: 47**) and CDR_3 (**SEQ ID NO: 49**) of the heavy chain of PRCA157.

Claim 3. The isolated antibody or immunoreactive fragment thereof of any one of claims 1-2, wherein said antibody binds to B7-H3 that is endogenously expressed on the surface of a cancer cell.

Claim 4. The isolated antibody or immunoreactive fragment thereof of any one of claims 1-2, wherein said antibody binds to B7-H3 that is internalized upon binding to B7-H3 expressed on the surface of a cancer cell.

Claim 5. The isolated antibody or immunoreactive fragment thereof of any of claims 1-4, which is a humanized monoclonal antibody.

Claim 6. The isolated antibody of any of claims 1-5, wherein said antibody is a modified antibody that comprises a variant human IgG1 Fc region, wherein said variant human IgG1 Fc region comprises at least one amino acid modification relative to the Fc region of the parent of said antibody, said amino acid modification(s) comprising amino acid modification(s) that alters the affinity or avidity of said variant Fc region

for binding to an FcγR such that said modified antibody exhibits enhanced effector function relative to said parent antibody.

Claim 7. The antibody of claim 6, wherein said Fc region modification comprises:

(A) at least one substitution selected from the group consisting of:

(1) F243L;

(2) D270E;

(3) R292P;

(4) S298N;

(5) Y300L;

(6) V305I;

(7) A330V; and

(8) P396L;

(B) at least one substitution of two amino acid residues, said substitutions being selected from the group consisting of:

(1) F243L and P396L;

(2) F243L and R292P; and

(3) R292P and V305I;

(C) at least one substitution of three amino acid residues, said substitutions being selected from the group consisting of:

(1) F243L, R292P and Y300L;

(2) F243L, R292P and V305I;

(3) F243L, R292P and P396L; and

(4) R292P, V305I and P396L;

(D) at least one substitution of four amino acid residues, said substitutions being selected from the group consisting of:

(1) F243L, R292P, Y300L and P396L; and

(2) F243L, R292P, V305I and P396L;

or

(E) a substitution of at least the five amino acid residues: F243L, R292P, Y300L, V305I and P396.

Claim 8. The antibody of claim 7, wherein said antibody comprises substitutions of:

(A) F243L, R292P, and Y300L;

(B) L235V, F243L, R292P, Y300L, and P396L; or

(C) F243L, R292P, Y300L, V305I, and P396L.

Claim 9. The antibody of claim 8, wherein said antibody comprises comprises:

(A) a variable domain that comprises CDR_1 (**SEQ ID NO: 5**), CDR_2 (**SEQ ID NO: 7**) and CDR_3 (**SEQ ID NO: 9**) of the light chain of BRCA84D and CDR_1 (**SEQ ID NO: 13**), CDR_2 (**SEQ ID NO: 15**) and CDR_3 (**SEQ ID NO: 17**) of the heavy chain of BRCA84D; and

(B) an Fc region modification that comprises the substitutions: L235V, F243L, R292P, Y300L, and P396L.

Claim 10. The antibody of claim 9, wherein said antibody is a chimeric antibody.

Claim 11. The antibody of claim 9, wherein said antibody is a humanized antibody.

Claim 12. The isolated antibody or immunoreactive fragment thereof of claim 1, wherein said antibody comprises:

(A) a variable light chain having the amino acid sequence of hBRCA84D-2 VL (**SEQ ID NO: 89**);

(B) a variable heavy chain having the amino acid sequence of hBRCA84D-2 VH (**SEQ ID NO: 99**); and

(C) an Fc-region having the substitutions: L235V, F243L, R292P, Y300L, and P396L.

Claim 13. A hybridoma that secretes a monoclonal antibody that specifically binds an extracellular domain of B7-H3, wherein said antibody competes for binding to said B7-H3 with any of antibodies: BRCA69D, BRCA84D, or PRCA157.

Claim 14. A nucleic acid molecule that encodes the isolated antibody of any of claims 1-12 or the immunoreactive fragment of any of claims 1-5.

Claim 15. A dual affinity retargeting reagent (DART™), said reagent comprising:

(A) a polypeptide chain I that comprises an immunoglobulin VL epitope binding domain specific for binding B7-H3 and a VH epitope binding domain specific for binding a molecule other than B7-H3; and

(B) a polypeptide chain II that comprises an immunoglobulin VH epitope binding domain specific for binding B7-H3 and a VL epitope binding domain specific for binding said molecule other than B7-H3;

wherein said polypeptide chains I and II are associated together so as to form functional epitope binding domains capable of binding to B7-H3 and said molecule other than B7-H3.

Claim 16. The dual affinity retargeting reagent (DART™) of claim 15, wherein said molecule other than B7-H3 that may be bound by said DART™ is a hapten.

Claim 17. The dual affinity retargeting reagent (DART™) of claim 16, wherein said hapten is fluorescein isothiocyanate.

Claim 18. The dual affinity retargeting reagent (DART™) of claim 15, wherein said molecule other than B7-H3 that may be bound by said DART™ is a T-Cell Receptor or the NKG2D receptor.

Claim 19. The dual affinity retargeting reagent (DART™) of claim 15, wherein said molecule other than B7-H3 that may be bound by said DART™ is a tumor-associated antigen.

Claim 20. The dual affinity retargeting reagent (DART™) of claim 19, wherein said tumor-associated antigen is selected from the group consisting of A33; ADAM-9; ALCAM; BAGE; beta-catenin; CA125; Carboxypeptidase M; CD103; CD19; CD20; CD22; CD23; CD25; CD27; CD28; CD36; CD40/CD154; CD45; CD46; CD5; CD56; CD79a/CD79b; CDK4; CEA; CTLA4; Cytokeratin 8; EGF-R; EphA2; ErbB1; ErbB3; ErbB4; GAGE-1; GAGE-2; GD2/GD3/GM2; gp100; HER-2/neu; human papillomavirus-E6; human papillomavirus-E7; Integrin Alpha-V-Beta-6; JAM-3; KID3; KID31; KSA (17-1A); LUCA-2; MAGE-1; MAGE-3; MART; MUC-1; MUM-1; N-acetylglucosaminyltransferase; Oncostatin M; p15; PIPA; PSA; PSMA; ROR1; sTn; TNF-ß receptor; TNF-α receptor; TNF-γ receptor; Transferrin Receptor; and VEGF receptor.

Claim 21. A nucleic acid molecule that encodes a polypeptide chain of the dual affinity retargeting reagent (DART™) of any of claims 15-20.

Claim 22. A pharmaceutical composition comprising (i) a therapeutically effective amount of the isolated antibody of any of claims 1-12 or the immunoreactive fragment of any of claims 1-5 or the dual affinity retargeting reagent (DART™) of any of claims 15-20 and (ii) a pharmaceutically acceptable carrier.

Claim 23. The pharmaceutical composition of claim 21, wherein said antibody is a humanized antibody that comprises:

(A) a variable domain that comprises CDR_1 (**SEQ ID NO: 5**), CDR_2 (**SEQ ID NO: 7**) and CDR_3 (**SEQ ID NO: 9**) of the light chain of BRCA84D and CDR_1 (**SEQ ID NO: 13**), CDR_2 (**SEQ ID NO: 15**) and CDR_3 (**SEQ ID NO: 17**) of the heavy chain of BRCA84D; and

(B) an Fc region modification that comprises the substitutions: L235V, F243L, R292P, Y300L, and P396L.

Claim 24. The pharmaceutical composition of claim 21, wherein said antibody is a humanized antibody that comprises:

(A) a variable light chain having the amino acid sequence of hBRCA84D-2 VL (**SEQ ID NO: 89**);

(B) a variable heavy chain having the amino acid sequence of hBRCA84D-2 VH (**SEQ ID NO: 99**); and

(C) an Fc-region having the substitutions: L235V, F243L, R292P, Y300L, and P396L.

Claim 25. The pharmaceutical composition of any of claims 22-24, which further comprises one or more additional anti-cancer agents.

Claim 26. The pharmaceutical composition of any of claims 22-24 wherein said additional anti-cancer agent is a chemotherapeutic agent, a radiation therapeutic agent, a hormonal therapeutic agent, a toxin or an immunotherapeutic agent.

Claim 27. The pharmaceutical composition of any of claims 22-24 wherein said additional anti-cancer agent is a toxin selected from the group consisting of: a taxane, a maytansinoid, an auristatin, a calicheamicin, an anthracycline, a CC-1065 analog, docetaxel, a cathepsin, ricin, gelonin, *Pseudomonas* exotoxin, diphtheria toxin, RNase, and a toxic radioisotope.

Claim 28. The use of the isolated antibody of any of claims 1-12 or the immunoreactive fragment of any of claims 1-5 or the dual affinity retargeting reagent (DART™) of any of claims 15-20 in the diagnosis of cancer, wherein said isolated antibody, immunoreactive fragment, or DART™ is detectably labeled.

Claim 29. The use of claim 28, characterised in that said cancer is characterized by the presence of a cancer cell selected from the group consisting of a cell of an adrenal gland tumor, an AIDS-associated cancer, an alveolar soft part sarcoma, an astrocytic tumor, bladder cancer, bone cancer, a brain and spinal cord cancer, a metastatic brain tumor, a breast cancer, a carotid body tumors, a cervical cancer, a chondrosarcoma, a dhordoma, a chromophobe renal cell carcinoma, a clear cell carcinoma, a colon cancer, a colorectal cancer, a cutaneous benign fibrous histiocytoma, a desmoplastic small round cell tumor, an ependymoma, a Ewing's tumor, an extraskeletal myxoid

chondrosarcoma, a fibrogenesis imperfecta ossium, a fibrous dysplasia of the bone, a gallbladder or bile duct cancer, gastric cancer, a gestational trophoblastic disease, a germ cell tumor, a head and neck cancer, hepatocellular carcinoma, an islet cell tumor, a Kaposi's Sarcoma, a kidney cancer, a leukemia, a lipoma/benign lipomatous tumor, a liposarcoma/malignant lipomatous tumor, a liver cancer, a lymphoma, a lung cancer, a medulloblastoma, a melanoma, a meningioma, a multiple endocrine neoplasia, a multiple myeloma, a myelodysplastic syndrome, a neuroblastoma, a neuroendocrine tumors, an ovarian cancer, a pancreatic cancer, a papillary thyroid carcinoma, a parathyroid tumor, a pediatric cancer, a peripheral nerve sheath tumor, a phaeochromocytoma, a pituitary tumor, a prostate cancer, a posterious unveal melanoma, a rare hematologic disorder, a renal metastatic cancer, a rhabdoid tumor, a rhabdomysarcoma, a sarcoma, a skin cancer, a soft-tissue sarcoma, a squamous cell cancer, a stomach cancer, a synovial sarcoma, a testicular cancer, a thymic carcinoma, a thymoma, a thyroid metastatic cancer, and a uterine cancer.

Claim 30. The use of the isolated antibody of any of claims 1-12 or the immunoreactive fragment of any of claims 1-5 or the dual affinity retargeting reagent (DART™) of any of claims 15-20 or of the pharmaceutical composition of any of claims 22-27 in the preparation of a medicament for the treatment of cancer in a patient.

Claim 31. The use of any of claims 29-30, characterised in that said cancer is characterized by the presence of a cancer cell selected from the group consisting of a cell of an adrenal gland tumor, an AIDS-associated cancer, an alveolar soft part sarcoma, an astrocytic tumor, bladder cancer, bone cancer, a brain and spinal cord cancer, a metastatic brain tumor, a breast cancer, a carotid body tumors, a cervical cancer, a chondrosarcoma, a dhordoma, a chromophobe renal cell carcinoma, a clear cell carcinoma, a colon cancer, a colorectal cancer, a cutaneous benign fibrous histiocytoma, a desmoplastic small round cell tumor, an ependymoma, a Ewing's tumor, an extraskeletal myxoid chondrosarcoma, a fibrogenesis imperfecta ossium, a fibrous dysplasia of the bone, a gallbladder or bile duct cancer, gastric cancer, a gestational trophoblastic disease, a germ cell tumor, a head and neck cancer, hepatocellular carcinoma, an islet cell tumor, a Kaposi's Sarcoma, a kidney cancer, a leukemia, a lipoma/benign lipomatous tumor, a liposarcoma/malignant lipomatous tumor, a liver cancer, a lymphoma, a lung cancer, a medulloblastoma, a melanoma, a meningioma, a multiple endocrine neoplasia, a multiple myeloma, a myelodysplastic syndrome, a neuroblastoma, a neuroendocrine tumors, an ovarian cancer, a pancreatic cancer, a papillary thyroid carcinoma, a parathyroid tumor, a pediatric cancer, a peripheral nerve sheath tumor, a

phaeochromocytoma, a pituitary tumor, a prostate cancer, a posterious unveal melanoma, a rare hematologic disorder, a renal metastatic cancer, a rhabdoid tumor, a rhabdomysarcoma, a sarcoma, a skin cancer, a soft-tissue sarcoma, a squamous cell cancer, a stomach cancer, a synovial sarcoma, a testicular cancer, a thymic carcinoma, a thymoma, a thyroid metastatic cancer, and a uterine cancer.

Claim 32. The use of any of claims 29-31, characterised in that the use further comprises administration of one or more additional cancer therapies selected from the group consisting of chemotherapy, immunotherapy, radiation therapy, hormonal therapy, and surgery.